Immatics NV
IMTX
Company Profile
Business description
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
Contact
Paul-Ehrlich-Strasse 15
TubingenBW72076
DEUT: +49 707153970
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
423
Stocks News & Analysis
stocks
What to expect from the January Fed meeting
Central bankers are likely to hold interest rates steady, but Wall Street is focused on life after Powell.
stocks
Fortescue costs outpace increasing volume
Higher diesel prices and foreign exchange hit unit cash costs.
stocks
A top global stock to buy after a big change in its forecast
Undervalued by 24%, this wide-moat stock is a buy now.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,268.50 | 10.00 | 0.11% |
| CAC 40 | 8,167.58 | 36.43 | 0.45% |
| DAX 40 | 24,948.11 | 15.03 | 0.06% |
| Dow JONES (US) | 49,062.45 | 349.95 | -0.71% |
| FTSE 100 | 10,227.51 | 78.66 | 0.78% |
| HKSE | 27,126.95 | 361.43 | 1.35% |
| NASDAQ | 23,721.98 | 120.63 | 0.51% |
| Nikkei 225 | 53,333.54 | 448.29 | 0.85% |
| NZX 50 Index | 13,510.88 | 50.14 | 0.37% |
| S&P 500 | 6,965.23 | 15.00 | 0.22% |
| S&P/ASX 200 | 8,941.60 | 14.90 | 0.17% |
| SSE Composite Index | 4,139.90 | 7.30 | 0.18% |